# Biotech Daily Digest â€” 2025-11-22

**10 items from 2 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 3 items


## Endpoints News

- **[Makaryâ€™s user fee comments; M&A activity stays hot; A new use for prime editing; and more](https://endpoints.news/makarys-user-fee-comments-m-a-new-use-for-prime-editing-and-more/)**  
  _Sat, 22 Nov 2025 11:00:03 +0000_  
  Welcome back to another edition of Endpoints Weekly. Our Saturday newsletter will be off next week for Thanksgiving, so let us be the first to wish you all a happy and healthy holiday! Iâ€™m personally ...

- **[AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the US](https://endpoints.news/astrazeneca-to-onshore-rare-disease-portfolio-as-part-of-its-50b-pledge-to-the-us/)**  
  _Fri, 21 Nov 2025 19:33:41 +0000_  
  AstraZeneca will invest $2 billion to expand its presence in Maryland, its latest move to boost US manufacturing as part of a larger $50 billion pledge, the company announced Friday.

 The UK-based drugmaker will use ...

- **[Teva loses IRA drug pricing challenge in DC federal court](https://endpoints.news/teva-loses-ira-drug-pricing-challenge-in-dc-federal-court/)**  
  _Fri, 21 Nov 2025 19:19:47 +0000_  
  Tevaâ€™s challenge against Medicare negotiations fell flat in DC federal court, marking another loss for the pharma industry.

 US District Judge Sparkle Sooknanan said Thursday that Tevaâ€™s constitutional and statutory claims ...

- **[Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna](https://endpoints.news/sarepta-ends-elevidys-trial-with-hansas-pre-treatment-some-pipeline-cuts-at-moderna/)**  
  _Fri, 21 Nov 2025 16:12:27 +0000_  
  Plus, news about Blue Lake, Bambusa, Inhibikase Therapeutics and Olema Oncology:

 ðŸ›‘ Sarepta terminates Elevidys trial with Hansa Biopharmaâ€™s imlifidase: The study was examining whether Hansaâ€™s imlifidase, an IgG antibody-cleaving enzyme, could help reduce ...

- **[Novo, Lilly begin to sell obesity medications directly to employers](https://endpoints.news/novo-lilly-begin-to-sell-obesity-medications-directly-to-employers/)**  
  _Fri, 21 Nov 2025 15:56:08 +0000_  
  Building on the growing success of offering cheaper cash-pay prices to consumers for their GLP-1 weight loss drugs, Novo Nordisk and Eli Lilly are setting up programs to work directly with employers.

 Waltz Health, an ...

- **[Lilly becomes first $1 trillion pharma company](https://endpoints.news/lilly-becomes-first-1t-pharma-company/)**  
  _Fri, 21 Nov 2025 15:24:53 +0000_  
  Eli Lilly's market valuation briefly reached more than a trillion dollars on Friday, making it the first-ever drugmaker to reach that benchmark.

 It hit the 13-digit valuation during intraday trading Friday, according to reports from ...

- **[Contineum's J&J-partnered drug fails Phase 2 multiple sclerosis trial](https://endpoints.news/contineums-jj-partnered-drug-fails-phase-2-multiple-sclerosis-trial/)**  
  _Fri, 21 Nov 2025 15:19:47 +0000_  
  Contineum Therapeutics reported a Phase 2 failure in multiple sclerosis on Thursday afternoon, but most analysts donâ€™t seem to view the miss as catastrophic.

 Contineum said its drug PIPE-307 did not ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation" hreflang="en">In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation</a>](https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation)**  
  _Nov 21, 2025 4:16pm_  
  Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDAâ€™s ability to function.

- **[<a href="https://www.fiercebiotech.com/medtech/roche-inks-200m-licensing-pact-freenomes-cancer-screening-blood-tests" hreflang="en">Roche inks $200M+ licensing pact for Freenome's cancer screening blood tests</a>](https://www.fiercebiotech.com/medtech/roche-inks-200m-licensing-pact-freenomes-cancer-screening-blood-tests)**  
  _Nov 21, 2025 10:57am_  
  Roche will make a new $75 million equity investment in Freenome, toward the goal of developing blood testing kits for markets outside the U.S.

- **[<a href="https://www.fiercebiotech.com/pharma/gsks-tesaro-and-licensor-anaptysbio-lock-horns-court-over-jemperli-agreement" hreflang="en">GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement</a>](https://www.fiercebiotech.com/pharma/gsks-tesaro-and-licensor-anaptysbio-lock-horns-court-over-jemperli-agreement)**  
  _Nov 21, 2025 9:33am_  
  Some four years into Jemperliâ€™s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbusterâ€™s original developer, AnaptysBio.
